We are live on ! Find out more
PR

PSP Research Portfolio holdings

AUM $188M
This Fund
S&P 500
This Quarter Est. Return
+18.09%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$114M
AUM Growth
–
Cap. Flow
+$110M
Cap. Flow %
96.55%
Top 10 Hldgs %
65.84%
Holding
85
New
85
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
SGOV icon
iShares 0-3 Month Treasury Bond ETF
SGOV
+$70.3M
2
LEGN icon
Legend Biotech
LEGN
+$699K
3
ACLX
Arcellx
ACLX
+$656K
4
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$601K
5
MLYS icon
Mineralys Therapeutics
MLYS
+$594K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 38.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLYS icon
26
Mineralys Therapeutics
MLYS
$2.29B
$538K 0.47%
+14,818
New +$594K
ACLX
27
DELISTED
Arcellx
ACLX
$536K 0.47%
+8,224
New +$656K
PTCT icon
28
PTC Therapeutics
PTCT
$6.07B
$535K 0.47%
+7,046
New +$512K
ZYME icon
29
Zymeworks
ZYME
$2.1B
$535K 0.47%
+20,312
New +$443K
SUPN icon
30
Supernus Pharmaceuticals
SUPN
$2.61B
$535K 0.47%
+10,758
New +$523K
PTGX icon
31
Protagonist Therapeutics
PTGX
$9.8B
$535K 0.47%
+6,121
New +$501K
HRMY icon
32
Harmony Biosciences
HRMY
$2.31B
$534K 0.47%
+14,283
New +$470K
ROIV icon
33
Roivant Sciences
ROIV
$26.5B
$534K 0.47%
+24,621
New +$486K
RPRX icon
34
Royalty Pharma
RPRX
$27.5B
$534K 0.47%
+13,826
New +$527K
AMLX icon
35
Amylyx Pharmaceuticals
AMLX
$4.13B
$534K 0.47%
+44,223
New +$601K
LQDA icon
36
Liquidia Corp
LQDA
$6.39B
$534K 0.47%
+15,485
New +$441K
TARS icon
37
Tarsus Pharmaceuticals
TARS
$3.1B
$534K 0.47%
+6,519
New +$487K
PVLA
38
Palvella Therapeutics
PVLA
$2.22B
$532K 0.47%
+5,084
New +$434K
RAPP
39
Rapport Therapeutics
RAPP
$2.52B
$531K 0.46%
+17,506
New +$484K
TGTX icon
40
TG Therapeutics
TGTX
$8.42B
$531K 0.46%
+17,807
New +$582K
INSM icon
41
Insmed
INSM
$27.2B
$531K 0.46%
+3,049
New +$556K
LEGN icon
42
Legend Biotech
LEGN
$4.02B
$530K 0.46%
+24,397
New +$699K
ARGX icon
43
argenx
ARGX
$65.5B
$530K 0.46%
+630
New +$539K
NBIX icon
44
Neurocrine Biosciences
NBIX
$15.9B
$530K 0.46%
+3,734
New +$541K
NUVL
45
DELISTED
Nuvalent
NUVL
$529K 0.46%
+5,261
New +$519K
INCY icon
46
Incyte
INCY
$26B
$528K 0.46%
+5,350
New +$518K
CYTK icon
47
Cytokinetics
CYTK
$11B
$528K 0.46%
+8,313
New +$517K
VRDN icon
48
Viridian Therapeutics
VRDN
$2.75B
$528K 0.46%
+16,967
New +$465K
ACAD icon
49
Acadia Pharmaceuticals
ACAD
$5.1B
$528K 0.46%
+19,766
New +$472K
WVE icon
50
Wave Life Sciences
WVE
$1.03B
$528K 0.46%
+31,040
New +$315K
1
2
3 4

Similar funds

IJWM
Inman Jager Wealth Management Hattiesburg, Mississippi $188M AUM 19.49% 1-Year Est. Return
TCPG
Trivant Custom Portfolio Group San Diego, California $188M AUM 23.55% 1-Year Est. Return
KCPT
Kingstone Capital Partners Texas Frisco, Texas $188M AUM 26.67% 1-Year Est. Return
DWS
Dynamic Wealth Strategies Granite Bay, California $188M AUM 18.55% 1-Year Est. Return
RMSCM
R.M. Sincerbeaux Capital Management New York $188M AUM 12.59% 1-Year Est. Return
AWP
Astra Wealth Partners Jersey City, New Jersey $188M AUM 26.79% 1-Year Est. Return
AIMA
Ables Iannone Moore & Associates Savannah, Georgia $188M AUM 26.75% 1-Year Est. Return
CFP
Comprehensive Financial Planning East Petersburg, Pennsylvania $188M AUM 48.26% 1-Year Est. Return

PSP Research's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for PSP Research, which disclosed 85 positions worth $114M. Its ten largest holdings account for 66% of the portfolio.

Its largest position is iShares 0-3 Month Treasury Bond ETF: 700,000 shares worth $70.3M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets.

  • PSP Research's largest Q4 2025 buy was iShares 0-3 Month Treasury Bond ETF: 700,000 shares worth $70.3M.
  • PSP Research's ten largest holdings make up 66% of its $114M portfolio in Q4 2025.
  • PSP Research disclosed 85 positions in Q4 2025, its first 13F filing on record.

Based on PSP Research's 13F filing for Q4 2025, filed 6 Feb 2026.